Michel Drouin
Keine laufenden Positionen mehr
Profil
Michel Drouin worked as an Executive Medical Director at Mirati Therapeutics, Inc. and as a Vice President-Business Development at Aur Resources, Inc.
Ehemalige bekannte Positionen von Michel Drouin
| Unternehmen | Position | Ende |
|---|---|---|
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 09.07.2009 |
Aur Resources, Inc.
 Aur Resources, Inc. Other Metals/MineralsNon-Energy Minerals Aur Resources, Inc. is a Canadian-based, international mining company active in the acquisition, exploration, development and mining of mineral properties with a strong emphasis on copper. Over 95% of Aur’s revenue comes from the production of copper at its Quebrada Blanca, Andacollo and Louvicourt Mines. Aur is currently developing its Duck Pond copper-zinc deposit for production and conducting feasibility studies with a view to potentially developing the Andacollo primary copper deposit for production | Corporate Officer/Principal | 22.01.2009 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Aur Resources, Inc.
Aur Resources, Inc. Other Metals/MineralsNon-Energy Minerals Aur Resources, Inc. is a Canadian-based, international mining company active in the acquisition, exploration, development and mining of mineral properties with a strong emphasis on copper. Over 95% of Aur’s revenue comes from the production of copper at its Quebrada Blanca, Andacollo and Louvicourt Mines. Aur is currently developing its Duck Pond copper-zinc deposit for production and conducting feasibility studies with a view to potentially developing the Andacollo primary copper deposit for production | Non-Energy Minerals |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
